Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology
Does the molecular subtype of breast cancer influence your decision to give hypofractionated radiotherapy?
Should hypofractionation be avoided in triple negative disease?
Answer from: Radiation Oncologist at Community Practice
I heard Jay Harris speak at ACRO last year and the Dana Farber/Brigham has a personalized BCT approach based on molecular subtype
‘Personalized’ BCT based on Subtype, Age (DFCI/BWH)
Luminals Age > 60: 266 x 16, no boost
Luminals Age 50-60: 266 x 15, 250 x 2
HER2+...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
At this point for patients who need breast RT only we do not distinguish based on phenotye for offering hypofractionation . Start B did not see any difference in outcome in any sub category. Whelan data when reviewed showed no difference in outcome for two fractionation for nottingham grade 3 diseas...
Answer from: Radiation Oncologist at Community Practice
It’s not exactly obvious to me that there is any example where response to radiotherapy fraction size alone is affected by tumor grade alonewithin a particular disease subsite. This should be clearly distinguished from the potential/theoretical benefit of dose escalation in biolog...
Answer from: Radiation Oncologist at Academic Institution
The new ASTRO guideline on whole breast fractionation recently published in Practical Radiation Oncology (PRO) recommended that the decision to offer hypofractionation should be independent of grade, ER, PR, Her2/neu status or margin status. There was 100% consensus on this question by the panel of ...